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Human immunodeficiency virus type 1 (HIV-1) infection, still represent a serious global
health emergency. The chronic toxicity derived from the current anti-retroviral therapy
limits the prolonged use of several antiretroviral agents, continuously requiring the
discovery of new antiviral agents with innovative strategies of action. In particular, the
development of single molecules targeting two proteins (dual inhibitors) is one of the
current main goals in drug discovery. In this contest, metal-chelating molecules have
been extensively explored as potential inhibitors of viral metal-dependent enzymes,
resulting in some important classes of antiviral agents. Inhibition of HIV Integrase
(IN) is, in this sense, paradigmatic. HIV-1 IN and Reverse Transcriptase-associated
Ribonuclease H (RNase H) active sites show structural homologies, with the presence
of two Mg(II) cofactors, hence it seems possible to inhibit both enzymes by means
of chelating ligands with analogous structural features. Here we present a series of
N′-acylhydrazone ligands with groups able to chelate the Mg(II) hard Lewis acid ions
in the active sites of both the enzymes, resulting in dual inhibitors with micromolar
and even nanomolar activities. The most interesting identified N′-acylhydrazone analog,
compound 18, shows dual RNase H-IN inhibition and it is also able to inhibit viral
replication in cell-based antiviral assays in the low micromolar range. Computational
modeling studies were also conducted to explore the binding attitudes of some model
ligands within the active site of both the enzymes.
Keywords: antiviral agents, HIV-1 integrase, RNase H, chelating pharmacophore, dual inhibitors, acylhydrazone
Abbreviations: CC50, 50% cytotoxic concentration; DTT, dithiothreitol; EC50, half maximal effective concentration; HIV-1,
Human Immunodeficiency Virus type 1; HTRF, Homogeneous Time Resolved Fluorescence; IC50, half maximal inhibitory
concentration; IN, integrase; LEDGF, lens epithelium-derived growth factor; PFV, prototype foamy virus; RNase H,
ribonuclease H; RT, reverse transcriptase.
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INTRODUCTION
Human Immunodeficiency Virus type 1 (HIV-1) is responsible of
the infection of 30 million people worldwide. The ssRNA HIV-1
genome retrotranscription into proviral dsDNA is a fundamental
step in the HIV-1 replication cycle. This process is carried out
by the viral coded RT, a multifunctional protein that catalyzes
different reactions combining the RNA- and DNA-dependent
DNA polymerase and RNase H activities, both essential for
viral replication (Esposito and Tramontano, 2014). After the
retrotranscription process, the viral enzyme IN allows the
integration of the HIV-1 genome into the host cell chromosome,
through two essential catalytic reactions, named 3′-processing
and strand-transfer (Esposito et al., 2015). Despite an effective
antiretroviral therapy has been developed, the incidence of HIV
infection continues to raise. The development of new drugs with
new mode of actions, such as single molecules that may act on
two different target enzymes or two different catalytic functions
(Patyar et al., 2011), would reduce the number of administered
drugs, their chronic toxicity and the chance of selecting drug
resistant viruses (Costi et al., 2014; Esposito and Tramontano,
2014); hence it remains one of the current main goals in drug
discovery.
Metal-chelating molecules have been extensively studied as
antivirals, resulting in the individuation of important classes of
metal-dependent enzyme inhibitors (Ronconi and Sadler, 2007;
Hocharoen and Cowan, 2009; Liao et al., 2010; Rogolino et al.,
2012; Barry and Sadler, 2013). In particular, drugs targeting
HIV-1 IN have evolved into an important component of the
currently used clinical protocols. Their mechanism of action
involves the chelation of the magnesium cofactors within the
active site of the HIV-1 IN enzyme. The first clinically developed
IN inhibitor (INI), raltegravir (Isentress R©), was approved in late
2007 (Summa et al., 2008; Hicks and Gulick, 2009). In 2012,
elvitegravir (Sato et al., 2006) and in 2013 dolutegravir (Kawasuji
et al., 2013) jointed the therapeutic pool, and other chelating IN
inhibitors are currently in clinical trials (Karmon and Markowitz,
2013).
Since HIV IN catalytic domain exhibits striking structural
similarities with the viral RT-associated RNase H domain
(Rogolino et al., 2012), the development of dual-acting drugs
targeting both viral IN and HIV-1 RT-associated RNase H
function has been proposed as an interesting strategy (Didierjean
et al., 2005; Billamboz et al., 2008; Marchand et al., 2008;
Corona et al., 2014a; Costi et al., 2014; Cuzzucoli Crucitti et al.,
2015). In fact, both HIV-1 IN and RNase H domains belong
to the polynucleotidyl transferases superfamily (Esposito and
Tramontano, 2014); these similarities allow to investigate the
structural features that a compound should hold to achieve a dual
IN/RNase H inhibition, taking advantage of the interactions that
an inhibitory compound can make with the amino-acidic lateral
chains that surround the catalytic core of both IN and RNase H
(Corona et al., 2016). It is worth noting that, despite the RNase
H function is a promising target for drug development (Corona
et al., 2014b) and different classes of compounds were reported
as potent inhibitors of the HIV-1 RNase H function (Esposito
et al., 2012; Corona et al., 2013), no RNase H inhibitors have
moved toward an advanced stage of (pre)clinical development.
N′-acylhydrazones represent an interesting class of chelating
ligands with a broad spectrum of antiviral activities (Borkow
et al., 1997; Rollas and Küçükgüzel, 2007), including HIV (Gong
et al., 2011; Sanchez et al., 2013; Herschhorn et al., 2014), vaccinia
virus (Abdel-Aal et al., 2006) and influenza virus (Chen et al.,
2014). Recently, we focused our attention on a family of N′-
acylhydrazones which proved to be versatile chelating inhibitors
of the influenza virus PA endonuclease (Carcelli et al., 2016).
We also identified some N′-acylhydrazone metal complexes with
promising in vitro antiviral activity against various DNA- and
RNA-viruses (Rogolino et al., 2015). Based on the functional
similarity between HIV IN, HIV RNase H and the influenza PA
endonuclease (Rogolino et al., 2012), we decided to evaluate a
panel of N′-acylhydrazones against both HIV IN and RNase H,
with the aim of identifying a unique chelating motif effective
across metal-dependent enzymes of diverse viruses. Herein we
present the biological evaluation in both enzymatic and cellular
assays of a series of chelating N′-acylhydrazones (compounds
1–23, Figure 1).
The structure-activity relationship for these compounds was
analyzed, based on their presumed metal binding modes, thus
identifying the chelating features involved in dual inhibition
of both HIV IN and RNase H. Interestingly, some of these
compounds (i.e., 18, 20, 21 and 23) inhibit the RT-associated
RNase H function in the micromolar and high nanomolar range.
In particular, compound 18 is also able to inhibit viral replication
in cell-based antiviral assays in the low micromolar range,
representing one of the best inhibition profiles so far reported.
Furthermore, computational modeling studies were conducted
for compound 18 and some model ligands to explore the binding
mode of these compounds within the active sites of the two HIV
enzymes.
MATERIALS AND METHODS
All reagents of commercial quality were used without further
purification. The purity of the compounds was determined by
elemental analysis and verified to be ≥95%. NMR spectra were
recorded at 25◦C on a Bruker Avance 400 FT spectrophotometer.
The attenuated total reflectance IR spectra were recorded by
means of a Nicolet-Nexus (Thermo Fisher) spectrophotometer
by using a diamond crystal plate in the range of 4000–400 cm−1.
Elemental analyses were performed by using a FlashEA
1112 series CHNS/O analyzer (Thermo Fisher) with gas-
chromatographic separation. Electrospray mass spectral analyses
(ESI-MS) were performed with an electrospray ionization (ESI)
time-of-flight Micromass 4LCZ spectrometer. MS spectra were
acquired in positive EI mode by means of a direct exposure
probe mounting on the tip of a Re-filament with a DSQII
Thermo Fisher apparatus, equipped with a single quadrupole
analyzer.
Chemistry
Compounds 1–23 were synthesized following literature methods
(Congiu and Onnis, 2013; Carcelli et al., 2016; Kim et al., 2016).
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FIGURE 1 | Schematic representation of N′-acylhydrazones 1–23.
Their characterization is reported in the Supplementary
Materials.
HIV-1 RT-associated RNase H Assays
Human immunodeficiency virus type 1 heterodimeric RT was
expressed and purified as previously described (Esposito et al.,
2011; Meleddu et al., 2014). The HIV-1 RT-associated RNase
H activity was measured as described (Corona et al., 2014a;
Meleddu et al., 2015). Briefly, 20 ng of HIV-1 RT was incubated
in 100 µL reaction volume containing 50 mM Tris-HCl
(pH 7.8), 6 mM MgCl2, 1 mM DTT, 80 mM KCl, hybrid
RNA/DNA (5′-GTTTTCTTTTCCCCCCTGAC-3′-Fluorescein,
5′-CAAAAGAAAAGGGGGGACUG-3′-Dabcyl) and 2 nM RT.
The reaction mixture was incubated for 1 h at 37◦C; the reaction
was stopped by addition of EDTA and products were measured
with a Victor 3 (Perkin Elmer model 1420-051) equipped with
filters for 490/528 nm (excitation/emission wavelength).
HIV-1 IN/LEDGF HTRF LEDGF
Dependent Assay
Recombinant IN and LEDGF/p75 were purified as described
(Esposito et al., 2015). The IN-LEDGF/p75 dependent assay
allows to measure the inhibition of 3′ processing and strand
transfer IN reactions in presence of recombinant LEDGF/p75
protein, as previously described (Tintori et al., 2015). Briefly,
50 nM IN was pre-incubated with increasing concentration of
compounds for 1 h at room temperature in reaction buffer
containing 20 mM HEPES pH 7.5, 1 mM DTT, 1% glycerol,
20 mM MgCl2, 0.05% Brij-35 and 0.1 mg/ml BSA. DNA donor
substrate, DNA acceptor substrate and 50 nM LEDGF/p75
protein were added and incubated at 37◦C for 90 min. After
the incubation, 4 nM of Europium-Streptavidin were added to
the reaction mixture and the HTRF signal was recorded using a
Perkin Elmer Victor 3 plate reader using a 314 nm for excitation
wavelength and 668 and 620 nm for the wavelength of the
acceptor and the donor substrates emission, respectively.
Cell-based HIV Assay
The procedure to determine anti-HIV activity and cytotoxicity of
the compounds in human lymphocyte MT-4 cells was published
elsewhere (Pannecouque et al., 2008). Briefly, serial dilutions
of the compounds were added to 96-well plates containing the
MT-4 cells. To the virus-infected wells, 100–300 CCID50 (50%
cell culture infectious dose-50%) of HIV-1 (strain IIIB) or HIV-
2 (strain ROD) was added. The mock-infected wells received
the compounds without the virus. After 5 days incubation, the
spectrophotometric MTT assay was performed to determine
the effect of the compounds on the viability of the mock- and
HIV-infected cells. The CC50 was defined as the compound
concentration that reduced the viability of the mock-infected
MT-4 cells by 50%. The concentration achieving 50% protection
from the virus-induced cytopathic effect was defined as the 50%
effective concentration (EC50).
Molecular Modeling
Crystal structures of the full-length mutant HIV-1 RT containing
RNase H domain and the PFV intasome as HIV-1 IN model,
were retrieved from RCSB Protein Data Bank (accession codes
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3LP2 and 5FRM, for RNase and IN, respectively). While the
5FRM was used as it is, the 3LP2 crystal was optimized by retro-
mutation to the wild type by substitution at 103 position of
Asparagine with Lysine, and then by insertion of the missed
residue Arg557, as previously described (Budihas et al., 2005).
Next, for both proteins, solvent and ligand molecules were
removed, hydrogens were added, and partial atomic charges were
assigned according to Amber99 force field, using MOE platform
(Molecular Operating Environment [MOE], 2009).
Ligands were constructed using the builder feature
implemented in MOE, and their energy was minimized
until a convergence gradient of 0.01 kJ (mol Å)−1 was reached
using the MMFF94x force field. Then, ligands were docked into
the catalytic pocket of both protein models using Alpha Triangle
Placement method. All docking parameters were kept as default.
The best docking pose of each ligand has been considered for
discussion and graphical representation.
RESULTS
Compounds Tested
N′-acylhydrazones 1–23 (Figure 1), prepared in high yields
as previously described (Congiu and Onnis, 2013; Carcelli
et al., 2016; Kim et al., 2016), were fully characterized by
spectroscopic tools, mass spectrometry and elemental analysis
(see Supplementary Materials). To modulate the lipophilicity
and hydrogen-bonding capabilities, we considered the N′-
(2,3-dihydroxybenzylidene)-scaffold and the N′-(2-hydroxy-3-
methoxybenzylidene)-analog and modified the acylhydrazonic
substituent by introducing the heptyl (1 and 2), phenyl (3
and 4), 2-hydroxyphenyl (5 and 6) and 3,4,5-trihydroxyphenyl
moiety (14 and 15). In order to investigate the role of hydroxyl
substituents, compounds carrying none (11), one (13), two
(14–18) or three (20–23) hydroxyl groups on the aromatic ring
A and a 3,4,5-trihydroxy moiety in B were synthesized.
Effect of Compounds on HIV-1 Functions
N′-acylhydrazones 1–23 were tested for their ability to inhibit
HIV-1 RT-associated RNase H activity as well as HIV-1 IN
activity in the presence of the human LEDGF/p75 cofactor
(Cherepanov et al., 2005) (Table 1). Moderate potency of
RNase H inhibition (IC50 about 60 µM) was observed when
N′-2,3-dihydroxy benzylidene heptyl hydrazone 1 and its analog
2 (Figure 1) were assayed. This potency of inhibition was
completely abolished when the heptyl chain was replaced by
an aromatic group (compounds 3 and 4). No inhibition of
the RNase H was observed by the 2,3-dihydroxybenzylidene
ligand 5, while the 2-hydroxy-3-methoxy analog 6 had moderate
activity (IC50 = 37 µM). N′-acylhydrazones 1–6 did not
inhibit IN activity in the presence of the LEDGF cofactor.
We then investigated the influence of hydroxyl substitution on
the aromatic ring A (Figure 2) within the series 7–10, which
possesses three hydroxyls at varying positions in A. In this series,
the position of the hydroxyl substituent improved the potency of
inhibition against RNase H function. In fact, compound 7 inhibits
the RNase H activity with an IC50 value of 25 µM, resulting
TABLE 1 | Inhibitory effect of compounds 1–23 on HIV-1 RT-associated
RNase H function and HIV-1 IN activity.





(1) 61 ± 11 >100




(6) 37 ± 5 >100
(7) 25.3 ± 7.6 7.1 ± 0.2
(8) 8.8 ± 3.1 30 ± 1
(9) 9.6 ± 3.4 9.4 ± 0.4
(10) 4.1 ± 0.2 >100
(11) 2.6 ± 0.6 >100
(12) 3.2 ± 0.5 >100
(13) 2.3 ± 0.7 >100
(14) 3.1 ± 0.5 >100
(15) 0.92 ± 0.02 >100
(16) 2.1 ± 0.1 69 ± 5
(17) 2.0 ± 0.5 >100
(18) 1.7 ± 0.1 16 ± 3
(19) >100 >100
(20) 0.17 ± 0.002 0.085 ± 0.025
(21) 0.62 ± 0.10 0.08 ± 0.01
(22) 9.7 ± 1.6 1.8 ± 0.1
(23) 0.18 ± 0.03 0.165 ± 0.025
RDS1643 7.5 ± 0.9 ND
RAL >50 0.058 ± 0.01
aCompound concentration required to reduce the HIV-1 RT-associated RNase H
activity by 50%. Mean values ± of three independent experiments. bCompound
concentration required to inhibit the HIV-1 IN catalytic activities by 50% in the
presence of LEDGF. Mean values ± of three independent experiments.
around sixfold less potent than compound 10, and revealing
the crucial role of the hydroxyl substituent in engaging efficient
interactions with the protein active site and in modulating the
activity of the chelating inhibitor. Then, we investigated the role
of different substitutions of A on N′-acylhydrazones carrying the
gallic moiety as B (Figure 2): series 11–18 showed interesting
potency of inhibition against the RNase H function (IC50 values
ranging from 0.9 to 3.2 µM), while only compounds 16 and 18
inhibited the IN reaction (IC50 = 69 and 16 µM, respectively).
We then tested the series 20–23, in which the
N′-acylhydrazone scaffold carries three hydroxyl substituents
on the aromatic ring A. When the OH groups were present in
2, 4 and 6 positions (compound 22), a potency of inhibition
in the micromolar range was observed for both viral enzymes
(IC50 = 9.7 µM for RNase H and 1.8 µM for IN). When
moving the 6-OH function to position 5, for instance in
compound 21, the potency of inhibition was considerably
improved, with IC50 values in the sub-micromolar range for
HIV RNase H (IC50 = 0.62 µM) and in the nanomolar range
for HIV IN (IC50 = 0.08 µM). Again, when a 3,4,5-trihydroxy
substituent was present (compound 23), the potency of RNase
H inhibition was similar to the one of compound 21, while
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FIGURE 2 | Schematic representation of the possible binding modes of
the studied N′-acylhydrazones.
inhibition of HIV IN was less efficient (IC50 = 0.16 µM). The
optimal combination resulted in the compound 20, which
bears a 2,3,4-trihydroxybenzylidene moiety as A and showed
inhibition in the nanomolar range for both HIV RNase H and IN
(IC50 = 0.175 and 0.085 µM, respectively).
In cell-based HIV assays, the best result was obtained for
compound 18 with an EC50 value for HIV-1 of 17 ± 4 µM
(mean ± SD of two independent tests; data not shown). This
molecule produced 55 to 82% inhibition of HIV-1-induced
cytopathic effect at a concentration of 25 µM. Since its CC50 was
61 µM, its selectivity index was unfortunately too low to perform
mechanistic studies. Besides, weak and poorly reproducible
HIV-1 inhibition was seen for compounds 21–23 with EC50
values in the range of 2–20 µM and CC50 values∼37 µM.
Docking Studies
In order to explore the putative binding mode of the prototype
compounds toward each target enzyme, a series of computational
docking studies on some representative compounds was assessed.
In addition to the most effective compound 18, we also selected
the compound 23, starting from the observation that among the
reported inhibitors within the 1–23 series, whose carrying a gallic
moiety on the N′-acylhydrazone scaffold are endowed with the
highest inhibitory activities against both enzymes. Additionally,
to highlight some critical features that determine the dual
inhibitory activity, compound 15 was chosen as a comparison,
because it shows a good RNase H inhibitory activity (IC50
0.92 µM), but it is devoid of anti-IN activity (IC50 > 100 µM).
Concerning the interaction with IN, when ligands 15, 18 and
23 were docked into the catalytic pocket of the PFV intasome
(Figure 3A), all of them showed a common binding mode,
involving the ring B: the gallic moiety is directed toward the
metal ions, providing coordination in full accordance with the
proposed mode B (Figures 2, 3B). In particular, the gallic moiety
appeared to be located in close proximity to the catalytic triad,
and this makes also possible the formation of two accessory
hydrogen bonds between the carboxylate groups of Asp185 and
Asp221, and the hydroxyl groups in positions 3 and 5 of the gallic
ring B (Figures 3C–E). Moreover, rings A and B are engaged
in arene–arene interactions with Tyr212, and with the aromatic
scaffold of the adenine 17 of the viral nucleic acid (crystallized
in the PFV intasome that we used as a model), respectively.
Furthermore, for the docked compounds, additional contacts
with residues Asp185, Gln186, Tyr212, and Pro214 were detected.
Analyzing the structure of compounds with the highest IN
inhibition activity, such as compounds 18 and 23, it can be
observed that they are characterized by the presence of three
hydroxyl substituents on aromatic ring A. These functionalities
would effectively stabilize the ligand-target complex by means
of two additional hydrogen bonds: the first with the hydroxyl
group of Tyr212, and the second one with the amide NH of
Gln186 (Figure 3E for 23). Deletion of one hydroxyl group,
as in compound 18, significantly reduced the ability to inhibit
IN, and only a residual inhibitory potency was detected. Also
in the case of IN inactive compound 15, the 2-hydroxy-3-
methoxy motif did not show such interactions, probably due
to the presence of only one hydrogen donor function, and/or
to the steric hindrance caused by the methoxy group that
prevents the correct orientation of the ring A within the cavity
formed by Gln 186 and Tyr212. Overall, these information would
corroborate the hypothesis that the inhibition of IN by these
compounds is significantly influenced by the stabilization effect
of the substituents present on the aromatic ring A.
Again, a close similarity between the hypothetical disposition
of our compounds and the crystal structure of marketed IN
inhibitor Raltegravir was observed (Supplementary Figure S1).
In particular, the gallic moiety aligned with the 4-carboxamide-
5-hydroxy-1-methyl-6-oxopyrimidine ring of Raltegravir, where
the three hydroxyl functions of gallate overlap with the
coordinating oxygens of raltegravir, while the ring A of 18 appears
to mimic the oxadiazole ring.
When the docking of the interaction with the selected
compounds and the RNase H domain was performed, results
showed a slightly different behavior. In Figure 4 the best docking
poses obtained for compounds 15, 18 and 23 within the catalytic
pocket of RNase H are represented. The predicted binding
modes of the ligands involve also in this case the gallic moiety
as chelating motif toward the metal ions, while the remaining
portion of the molecules accommodates inside a narrow pocket
lined by residues Gly444-Glu449, Arg557, and Asn474, and ring
A stacked between Arg448 and Arg557 (Figure 4A). The main
stabilizing interactions can be attributed to: (a) an arene–cation
interaction with the aromatic ring A and the guanidinium group
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FIGURE 3 | Binding mode of the top-ranked docking results for compounds 15 (cyan), 18 (green) and 23 (yellow) in the HIV-1 IN catalytic site: (A)
superimposition of predicted conformations for ligands 15, 18, and 23 within the catalytic pocket displayed as surface (blue, red, gray and orange colors indicate
mildly polar, hydrophilic, hydrophobic and metal cofactors regions, respectively); (B) schematized chelating mode for the model ligands; (C–E) close view of
predicted binding mode, where relevant residues interacting with ligands are depicted as thick lines. Metal cofactors are represented as orange spheres, hydrogen
bonds (purple) and arene-arene or arene-cation (green) interactions are depicted as dashed lines.
FIGURE 4 | Binding mode of the top-ranked docking results for compounds 15 (cyan), 18 (green) and 23 (yellow) at the HIV-1 RNase H catalytic site:
(A) superimposition of predicted conformations for ligands 15, 18, and 23 within the catalytic pocket displayed as surface (blue, red, gray and orange colors indicate
mildly polar, hydrophilic, hydrophobic and metal cofactors regions, respectively); (B) schematized chelating mode for the model ligands; (C–E) close view of
predicted binding mode, where relevant residues interacting with ligands are depicted as thick lines. Metal cofactors are represented as orange spheres, hydrogen
bonds (purple) and arene-arene or arene-cation (green) interactions are depicted as dashed lines.
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of Arg448; (b) a polar/hydrophilic interaction between ring A and
the hydrazone group with Arg557; (c) a hydrogen bond with the
carbonyl of hydrazone group and the amide NH of Ala446 and
(d) a hydrogen bond between the hydroxyl group in position 3
of gallic moiety and Gly444 (Figures 4C–E). As observed for IN,
also in this case the different inhibitory activities of the ligands
seems related to the substituents on ring A.
DISCUSSION
The coordinating versatility of N′-acylhydrazone ligands is
well-known (Albrecht et al., 2009; Ray et al., 2009; Rogolino et al.,
2015). If a 2-hydroxy substituted phenyl ring is present on the
backbone of the ligand, it can coordinate one or, depending on
denticity, two metal centers (M1 and M2 in Figure 2). Moreover,
if a gallic moiety is introduced as B (Figure 2), an additional
coordinating mode arises (MI and MII). In our recent studies,
this versatility was demonstrated to be at the basis of efficient
inhibition of influenza virus PA endonuclease, due to chelation of
the two metal ions in the catalytic center of the enzyme (Carcelli
et al., 2016). Hence we wanted to verify whether this versatility
could be exploited for the development of effective dual chelating
inhibitors of other metal-dependent enzymes, like HIV-1 RNase
H and IN, with two Mg(II) ions in the catalytic site.
In fact, while most of the tested compounds were able to
inhibit the RNase H function, compounds 7–9 showed also to be
able to inhibit the HIV-1 IN, envisaging the possibility to design
dual inhibitors, with a synergic effect against both HIV RNase H
and IN. Of note, the activity of compound 10 toward RNase H
is particularly interesting. In fact, compound 10, In fact, since
10 does not carry the 2-hydroxyphenyl group in A, it lacks the
possibility to chelate in a tridentate ONO fashion (Mode A in
Figure 2); however, it can coordinate two cations by means of
its three OH groups. This chelating mode was indeed observed in
the crystal structure of 23 complexed with the N-terminal part of
the influenza PA endonuclease, which showed that 23 chelates the
two manganese (II) cofactors through its gallic moiety (Carcelli
et al., 2016).
Results on compounds 10–23 indicated that more stringent
requirements should be met to obtain efficient inhibition of
HIV IN with these ligands, when none (11), one (13) or two
(14–18) hydroxyl groups are present on aromatic ring A, or even
when this is replaced by a pyridine moiety (12). Compounds
11–17 proved to be selective RNase H inhibitors. The goal of
identifying dual chelating inhibitors of both HIV-1 RNase H
and IN, was fulfilled in compound 18 and in the series 20–23,
where the N′-acylhydrazone scaffold carries three hydroxyl
substituents on the aromatic ring A. In particular, compound
18 inhibits RNase H function ninefold more potently that IN
activity and the HIV replication in the same micromolar range.
Compounds 20–23 inhibit both HIV enzymes more potently
than compound 18 and their inhibitory ability strongly depends
on the position of the hydroxyl substituents, but a different trend
has been detected for each enzyme, presumably attributable to
the interactions established within the two different active sites.
Compounds 20–23, unfortunately, showed poor reproducibility
in HIV replication assay, compared to compounds 18. This can
be due to lower solubility in cell culture, which prevented from
obtaining reliable data for this series. Compounds 18, on the
contrary, with inhibition of HIV replication of 17 µM, can be
considered a better hit. For compounds 11–18, chelation of
the metal cofactors according to mode B (Figure 2) could be
hypothesized. This is consistent with (i) the activity of compound
11 that cannot exhibit the chelating mode A because it lacks
the 2-OH group; (ii) the inactivity of compound 19, where the
gallic moiety is replaced by a 3,4,5-trimethoxy benzene ring.
Evidently, the 3,4,5-trihydroxybenzyl moiety in B is essential,
but not sufficient to ensure potent enzyme inhibition, since the
interactions of ring A, for example with the amino acid side
chains of the protein, appear to be crucial in modulating the
inhibitory activity.
For the compounds 20–23, we hypothesize that the inhibitory
activity of this gallic moiety-containing compound series is
determined by (i) the ability of chelating the metal ions in the
active site of the enzyme; and (ii) the presence and position of
the hydroxyl substituents in A, which may possibly yield relevant
ligand–protein interactions (e.g., through hydrogen bonds).
It has been reported that hydrazones have an interesting dual
inhibition profile, since they inhibit both RT-associated RNase
H and RDDP functions (Borkow et al., 1997). In particular,
hydrazones were reported to inhibit the RNase H function
(i) binding to an allosteric site located between the polymerase
active site and the non-nucleoside reverse transcriptase inhibitor
(NNRTI) pocket (Himmel et al., 2006); (ii) binding to a site
located between the RNase H active site and the connection
domain (Gong et al., 2011). Differently, our data support the
hypothesis that the present metal-chelating N′-acylhydrazone
series bind as chelating agents into the RNase H active site.
Intriguingly, striking similarities can be seen in the
coordination modes proposed for the best compound 18
and compounds 15 and 23 compared to those of some
3-hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides,
recently described as potent inhibitors of HIV-1 IN and RNase H
(Wu et al., 2016). In fact, compounds 15, 18 and 23 are predicted
to establish secondary interactions with PFV residues Asp185,
Tyr212, and Glu221, which correspond to HIV IN Asp116,
Tyr143 and Glu152 (Dayer, 2016). Moreover, compound 23
establish additional secondary interactions with the hydroxyl
group of Tyr212 and with the nitrogen of the peptidic bridge
between Asp185 and Gln186. Importantly, while residue
Tyr143 is known to be involved in the interaction with the
first generation IN Inhibitors (Corona et al., 2016), both the
catalytic Asp116 and Asn117 residues are part of a short, highly
conserved region (H114-G118) (Ceccherini-Silberstein et al.,
2009), that bridges the β4 sheet, with the α5 helix. Also of note
the fact that among the residues hypothesized to be involved
in the interaction between N′-acylhydrazone derivatives and
the HIV-1 RT RNase H domain, some exhibit a high degree of
conservation, even among patients treated with RT inhibitors
(Santos et al., 2008). In particular, residue Asn474 is part of the
RNase H primer grip motif and its mutation has been shown to
determine to a strong decrease in viral fitness (Dash et al., 2008).
Interestingly, residue Asn474 has been previously shown to
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play a crucial role also for pyrrolyl diketoacids binding (Corona
et al., 2014a) and hence it seems to be involved in the binding of
chelating agents to the RNase H active site.
Finally, aiming to develop dual HIV-1 RNase H – IN
inhibitors, it is also worth noting that the predicted interactions
obtained for the model ligands toward IN and RNase H would
suggest two different coordinating modes: while for IN it can
reasonably proposed the binding mode B (Figure 3B), in the case
of RNase H an alternative coordinative hypothesis can be invoked
(Figure 4B). In fact, docking results for ligands 15, 18 and 23
within the RNase H active site reveal that the gallic moiety is
oriented perpendicularly to the plane formed by metal cofactors
and the coordinating residues, with only two hydroxyl groups
involved in the chelation (Figure 4B). This unusual orientation
could depend on the presence, in the RNase H active site, of
a fourth residue (i.e., Asp549), which is able to provide for an
additional coordinating bond with a metal ion, thus blocking
a coordination site of the metal. This essential information is
clearly to be taken into account for further drug development of
dual target inhibitors.
CONCLUSION
The metal-chelating N′-acylhydrazones derivatives are a
good source to design dual inhibitors targeted to both
HIV-1 RT-associated RNase H and IN activities. The best
identified analog, compound 18, inhibits in the micromolar
range both RNase H and IN functions and is also able
to inhibit viral replication in the cell-based antiviral assay.
The computational docking studies performed support
the hypothesis that the N′-acylhydrazones derivatives can
chelate the metal ions in both HIV-1 RNase H and IN
active sites, and that the functional determinants for their
efficacy are different with respect to the two enzymes. This
information, together with the one that the binding of these
compounds in the enzyme catalytic sites can be stabilized
by the interaction with conserved amino acid residues,
will be essential for the development of further analog
optimization.
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